Drugs Made In America Acquisition Corp. (DMAAR)

NASDAQ · Holding & Investment Offices · Blank Checks

Price
$0.13
Day
+0.08%

Close 2026-09-24.

The company

Products and Services provided : Based on our team’s unique experience and skillset, we intend to source and evaluate companies focused on the AI, pharmaceutical, or any other sectors that need for rapid innovation. This non-exclusive list of criteria is not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on some or all of these general guidelines as well as other considerations, factors and criteria that our management may deem relevant. In the event that we decide to enter into our initial business combination with a target business that does not meet the above criteria and guidelines, we will disclose that the target business does not meet the above criteria in our shareholder communications related to our initial business combination, which would be in the form of proxy solicitation or tender offer materials that we would file with the SEC.

From Item 1: Products.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Recent filings